Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study

EClinicalMedicine, Год журнала: 2023, Номер 56, С. 101783 - 101783

Опубликована: Янв. 10, 2023

Язык: Английский

---

Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review

Journal of Autoimmunity, Год журнала: 2022, Номер 132, С. 102898 - 102898

Опубликована: Авг. 24, 2022

Язык: Английский

---

Post-COVID Syndrome in Adults—An Overview

Viruses, Год журнала: 2023, Номер 15(3), С. 675 - 675

Опубликована: Март 4, 2023

This article provides an overview of various aspects related to post-COVID syndrome. Apart from its prevalence, symptoms and sequelae, risk determinants, psychosocial implications, the pathogenesis condition is discussed in more detail. A focus on thrombo-inflammation SARS-CoV-2 infection, role neutrophil extracellular traps, prevalence venous thromboembolism made. Moreover, COVID-19 syndrome immunocompromising conditions, impact vaccination prevention treatment are reviewed. Autoimmunity a hallmark syndrome, and, therefore, another this article. Thus, misdirected cellular humoral immune responses can enhance latent autoimmunity Facing high cases worldwide, it be assumed that autoimmune disorders will increase globally over next few years. Recent advances identifying genetically determined variants may open avenue for better understanding susceptibility severity infection

Язык: Английский

---

Increased incidence of rheumatoid arthritis after COVID-19

Autoimmunity Reviews, Год журнала: 2023, Номер 22(10), С. 103409 - 103409

Опубликована: Авг. 18, 2023

Язык: Английский

---

Autoantibodies in COVID-19: implications for disease severity and clinical outcomes

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 6, 2025

Few pathogens have historically been subjected to as intense scientific and clinical scrutiny SARS-CoV-2. The genetic, immunological, environmental factors influencing disease severity post-infection outcomes, known correlates of immunity, remain largely undefined. Clinical outcomes SARS-CoV-2 infection vary widely, ranging from asymptomatic cases those with life-threatening COVID-19 symptoms. While most infected individuals return their former health fitness within a few weeks, some develop debilitating chronic symptoms, referred long-COVID. Autoimmune responses proposed one the long-COVID infection. association between viral infections autoimmune pathologies is not new. Viruses such Epstein-Barr virus cytomegalovirus, among others, shown induce production autoantibodies onset conditions. Given extensive literature on SARS-CoV-2, here we review current evidence SARS-CoV-2-induced pathologies, focus autoantibodies. We closely examine mechanisms driving autoantibody production, particularly connection

Язык: Английский

---

The global challenges of the long COVID-19 in adults and children

Travel Medicine and Infectious Disease, Год журнала: 2023, Номер 54, С. 102606 - 102606

Опубликована: Июнь 7, 2023

Язык: Английский

---

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

The Lancet Rheumatology, Год журнала: 2023, Номер 5(7), С. e375 - e385

Опубликована: Май 31, 2023

Язык: Английский

---

Post-COVID-19 syndrome: Insights into a novel post-infectious systemic disorder

Journal of Medicine and Life, Год журнала: 2023, Номер 16(2), С. 195 - 202

Опубликована: Фев. 1, 2023

Coronavirus disease 2019 (COVID-19) is currently considered a complex systemic infectious and inflammatory disease, determined by the infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), cause of one most important epidemiological phenomena in last century – COVID-19 pandemic. This infectious-inflammatory may generate wide range clinical manifestations biological modifications, explained ubiquitous nature SARS-CoV-2 receptors, represented angiotensin-converting enzyme-2 (ACE-2), host’s violent immune proinflammatory reaction to viral infection. These include immunological disturbances, which, according certain findings, persist post-infection, form presumed entity, defined several concepts common pathological significance: post-COVID-19 multisystem (or systemic) syndrome, post-COVID or long-COVID. Although pathophysiological mechanisms are elusive at present moment, there studies that describe autoimmune phenomenon following remission some patients, which suggests existence molecular cellular abnormalities, probably due initial response infection, three overlapping entities: secondary hemophagocytic lymph histiocytosis (HLH), macrophage activation (MAS) cytokine release (CRS). Thus, this reminiscent different classic diseases, various infections risk factors developing process.

Язык: Английский

---

Relationship between selenium status, selenoproteins and COVID-19 and other inflammatory diseases: A critical review

Journal of Trace Elements in Medicine and Biology, Год журнала: 2022, Номер 75, С. 127099 - 127099

Опубликована: Ноя. 3, 2022

Язык: Английский

---

Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies—An Interim Report

Journal of Clinical Medicine, Год журнала: 2023, Номер 12(19), С. 6428 - 6428

Опубликована: Окт. 9, 2023

There is increasing evidence for an autoimmune aetiology in post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). SARS-CoV-2 has now become the main trigger ME/CFS. We have already conducted two small proof-of-concept studies on IgG depletion by immunoadsorption (IA) ME/CFS, which showed efficacy most patients. This observational study aims to evaluate of IA patients with post-COVID-19 The primary objective was assess improvement functional ability. Due urgency finding therapies post-COVID-Syndrome (PCS), we report here interim results first ten patients, seven responders defined increase between 10 and 35 points Short-Form 36 Physical Function (SF36-PF) at week four after IA. this will provide basis patient selection a randomised controlled trial (RCT), including sham apheresis, RCT combining B-cell therapy. Trial registration number: NCT05629988.

Язык: Английский

---